Since the luminal subtype showed the most significant differences in survival between the high- and low-SKP2 ubiquitination groups, we asked next whether our SKP2 ubiquitination signature would be able to distinguish survival outcomes in hormone therapy in luminal-subtype BC patients. The gene discussed is SKP2; the disease is breast cancer.